A new study published in the Stroke journal revealed a crucial link between early fibrinogen depletion coagulopathy (FDC) and ...

Intravenous thrombolysis in patients hospitalized for cervical artery dissection-related acute ischemic stroke increases the likelihood of home discharge.

Citing a low hemorrhage rate and other issues, one expert says the results should be replicated before changing practice.

Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have ...

Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide ...

For patients with acute ischemic stroke, IV tenecteplase before endovascular thrombectomy is associated with higher functional independence at 90 days.

New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset. In the HOPE trial, administration of intravenous ...

Stroke patients with dementia treated with intravenous thrombolysis using powerful clot-busting drugs are at no higher risk of brain haemorrhage or death than other patients receiving the same ...

Individuals with STEMI caused by a spontaneous coronary artery dissection (SCAD) who are treated with intravenous thrombolysis prior to coronary angiography fare no worse in the hospital compared with ...

The authors looked at the efficacy and safety of intravenous thrombolysis with alteplase given within three to 4.5 hours after stroke symptom onset. A total of 821 acute stroke patients within ...